tirzepatide risks Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring Tirzepatide Side Effects: Common &

Mike, your dedicated physician

Talaat NB, Todorova D

Targeting metabolic dysfunction for the treatment of mood disorders: review of the evidence

(2021) trial tested cagrilintide at 0.3-4.5 mg weekly for 26 weeks in 706 adults: (Lau et al., 2021) Semaglutide Monotherapy (Phase 3) The STEP 1 trial tested semaglutide 2.4 mg weekly for 68 weeks in 1,961 adults: Mean weight loss: -14.9% =10% threshold: ~70% =15% threshold: ~54% =20% threshold: ~32% Important caveat: The semaglutide trial was 68 weeks versus only 26 weeks for cagrilintide

In PCOS, chronic anovulation leads to consistently low progesterone levels, contributing to an elevated LH-to-FSH ratio (Tsutsumi and Webster, 2009